OncoMatch/Clinical Trials/NCT07078591
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
Is NCT07078591 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for acute myeloid leukemia.
Treatment: GPBMC infusion · Venetoclax · Azacitidine (AZA) · Daunorubicin · Idarubicin（IDA） · Cytarabine (Ara-C) — The purpose of this study is to evaluate whether HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cell (GPBMC) infusion with venetoclax-containing regimens (microtransplant, MST) could improve survival in adult patients with newly diagnosed acute myeloid leukemia (AML).
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Prior therapy
Cannot have received: anti-acute leukemia treatment
Exception: prior hydroxyurea and/or leukapheresis are permitted
Lab requirements
Kidney function
serum creatinine <= 2 × ULN or CrCl >= 40 mL/min
Liver function
ALT and AST <= 3 × ULN, total bilirubin <= 1.5 × ULN
Cardiac function
LVEF > 50% by echocardiogram; no clinically significant cardiovascular disease (e.g., uncontrolled/highly symptomatic arrhythmias, CHF, MI within 6 months, NYHA class 3 or 4)
Adequate hepatic function including ALT and AST <= 3 × ULN, and total bilirubin <= 1.5 × ULN. Adequate renal function including serum creatinine <= 2 × ULN or CrCl >= 40mL/min. LVEF measured by echocardiogram is within the normal range (LVEF > 50%). Cardiovascular disease with clinical significance, such as uncontrolled or highly symptomatic cardiac arrhythmias, congestive heart failure, or myocardial infarction within 6 months prior to screening, or NYHA function class 3 (moderate) or class 4 (severe) heart disease [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify